Cansino Biologics (06185): Manhisin® drug supplement application accepted

^{Zhitong Finance App News, Cansino Biotech (06185) issued an announcement regarding the ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 vector) (MCV4, trade name: Manhisin®) “Drug Registration Certificate” granted to the company by the China National Drug Administration.} The company has obtained a “Notice of Acceptance” issued by the State Drug Administration. According to the notice, the State Drug Administration has accepted a supplementary application to expand the age range of people applicable to MCV4 from “children aged 3 months to 3 months (47 months)” to “children aged 3 months to 6 (83 months)”.

The company's MCV4 meningococcal quadrivalent conjugate vaccine product is China's first meningococcal quadrivalent conjugate vaccine product. Its launch has narrowed the gap between China and developed countries, filled the gap between China's lack of high-end vaccines in this field, and ^{provided a better solution} for the prevention of infantile encephalitis in China. MCV4 Manhisin ^® leverages its exclusive competitive advantage. The company continued to promote the promotion and market introduction of influenza vaccine products, and achieved a rapid increase in influenza vaccine revenue. In the first three quarters of 2024, the group achieved 516 million yuan in sales revenue for influenza vaccine products, and sales revenue for influenza vaccine products increased 39.07% year on year.